Sunlenca
Long-Acting Oral Combo for HIV Maintains Viral Suppression at Week 24
Most patients with HIV taking the investigational combination of islatravir (ISL; Merck) plus lenacapavir ...
JUNE 17, 2024
Oral Bridging of Lenacapavir Maintains Viral Suppression Among HIV Patients
Oral bridging of lenacapavir enabled patients to maintain viral suppression of their HIV after missed doses of ...
JULY 26, 2023
Lenacapavir’s Action May Curb HIV Infection Risk
Lenacapavir (Sunlenca, Gilead) may inhibit virion maturation by blocking the formation of HIV-capsid pentamers, ...
MAY 30, 2023
FDA Approves Sunlenca for Adults With Resistant HIV
The FDA approved lenacapavir, a first-in-class, long-acting HIV capsid inhibitor, which is injected twice ...
DECEMBER 22, 2022
Load more